Umang Vohra

Umang Vohra serves as Managing Director and Global CEO of Cipla Limited, one of India's largest and most storied pharmaceutical companies. Founded in 1935 by Khwaja Abdul Hamied, Cipla gained global recognition when it offered triple-combination HIV/AIDS therapy at $1 per day in 2001 — a move that helped save millions of lives across Africa and challenged Big Pharma's pricing paradigm for essential medicines. Under Vohra's leadership, Cipla has transformed from a predominantly Indian generics company into a diversified global pharmaceutical player. The company generates significant revenue from three core markets: India (where Cipla has top-3 market share in respiratory, cardiac, and urology), South Africa (Cipla is one of the largest pharmaceutical companies on the continent), and the United States (where Cipla is rapidly growing its complex generics and specialty portfolio including respiratory inhalers). Vohra's strategic priorities include expanding the U.S. specialty and complex generics pipeline (particularly inhaler products where Cipla has strong development capabilities), growing the peptide and biosimilar pipeline, consolidating Cipla's leadership in the Indian prescription market, and expanding the over-the-counter consumer healthcare business. His decisions on R&D investment in complex formulations, U.S. market expansion pace, India market share defense, and capital allocation are the primary drivers of the stock.